このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

腕に本態性振戦を有する成人参加者の治療のための NT 201 (ボツリヌス毒素) の有効性と安全性をプラセボと比較して調査する研究

2026年10月29日 更新者:Merz Pharmaceuticals GmbH

上肢の本態性振戦の片側性および両側性治療におけるNT 201の有効性と安全性を調査するための非盲検期間を伴う前向き、無作為化、二重盲検、プラセボ対照、並行群間試験

The purpose of this study is to determine whether a single treatment with NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the motor-dominant arm (Unilateral Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.

The following treatment cycle will investigate the safety and tolerability of two-sided treatment with NT 201 (botulinum toxin) (Open Label Bilateral Period). All participants will receive NT 201 treatment.

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

78

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Florida
      • Tampa、Florida、アメリカ、33612
        • USF, Department of Neurology, Merz Investigational Site #0010020
    • Nebraska
      • Omaha、Nebraska、アメリカ、68131
        • University of Nebraska Medical Center, Merz Investigational Site #0010269
    • Nevada
      • Las Vegas、Nevada、アメリカ、89106
        • Cleveland Clinic Lou Ruvo Center for Brain Health, Merz Investigational Site #0010457
    • New York
      • New York、New York、アメリカ、10029
        • Mount Sinai Medical Center, Merz Investigational Site #0010191
    • Tennessee
      • Nashville、Tennessee、アメリカ、37232
        • Vanderbilt University Medical Center, Neuroscience Institute, Merz Investigational Site #0010206
    • Texas
      • Houston、Texas、アメリカ、77030
        • Houston Methodist Neurological Institute, Merz Investigational Site #0010226
    • Virginia
      • McLean、Virginia、アメリカ、22101
        • Medstar Georgetown Neurology, Merz Investigational Site #0010231
    • Washington
      • Seattle、Washington、アメリカ、98195
        • UW Medical Center - Montlake, Merz Investigational Site #0010450
      • Spokane、Washington、アメリカ、99202
        • Selkirk Neurology, Merz Investigational Site #0010456
    • Ontario
      • London、Ontario、カナダ、N6A 5A5
        • London Health Sciences Centre, Merz Investigational Site #0010087
      • Krakow、ポーランド、30-539
        • Specjalistyczne Gabinety, Merz Investigational Site #0480059
      • Lodz、ポーランド、90-640
        • NeuroKlinika Gabinet Lekarski, Merz Investigational Site #0480101
      • Oświęcim、ポーランド、32-600
        • Instytut Zdrowia Dr. Boczarska-Jedynak
      • Warsaw、ポーランド、03-242
        • Mazowiecki Szpital Bródnowski, Merz Investigational Site #0480064

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

- Score of ≥ 2 (at least 1 cm tremor amplitude) in at least two out of three maneuvers of test item 4 (upper limb tremor) of the TETRAS performances scale confirmed by an independent TETRAS expert by means of video assessment.

Exclusion Criteria:

  • History or presence of day-to-day fluctuations in ET which would jeopardize meaningful tremor assessment over time, e.g. severe tremor on one day and minimal or no tremor on another day.
  • Other neurological signs, such as dystonia, ataxia, or parkinsonism, which in the judgment of the investigator could interfere with the ET diagnosis and/or assessment of ET in ULs.
  • Tremor types other than ET

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:NT 201 (IncobotulinumtoxinA, Xeomin)

Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the motor-dominant upper limb.

Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of both upper limbs.

Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

他の名前:
  • ゼオミン
  • ボツリヌス毒素A型(150キロダルトン)、複合タンパク質を含まない
  • インコボツリヌス毒素A
  • インコボツリヌス毒素 A
プラセボコンパレーター:Placebo

Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the motor-dominant upper limb.

Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of both upper limbs.

Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

他の名前:
  • ゼオミン
  • ボツリヌス毒素A型(150キロダルトン)、複合タンパク質を含まない
  • インコボツリヌス毒素A
  • インコボツリヌス毒素 A

Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist
時間枠:Baseline up to Week 6

TremorTek kinematic analytic investigational device is combination of computer software and wearable movement sensors that allows to collect motion data when placed on individual's arm to quantify tremor in various muscle groups that impact shoulder, elbow, wrist. This assessment system was used to measure maximum angular tremor amplitude at wrist of injected limb (unit: degrees). Angular tremor amplitude was measure of tremor severity. Reduction of maximum angular tremor amplitude at wrist of injected limb represented tremor improvement.

Baseline up to Week 6

二次結果の測定

結果測定
メジャーの説明
時間枠
Unilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator
時間枠:Baseline up to Week 6

The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 (including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

Baseline up to Week 6
Unilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score
時間枠:Baseline up to Week 6

TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items (on UL tremor [items 2-9]). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

Baseline up to Week 6
Unilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score
時間枠:Baseline up to Week 6

TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

Baseline up to Week 6
Unilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 6
時間枠:Week 6

The GICS was used to evaluate overall clinical impression of change after treatment by the subject. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

Week 6
Unilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 6
時間枠:Week 6

The GICS was used to evaluate the overall clinical impression of change after treatment by the investigator. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

Week 6
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score
時間枠:Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)

TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 ((including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score
時間枠:Baseline of Cycle 2 up to Week 6 (Cycle length =12 weeks)

The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. TETRAS performance subscale consisted of 9 items: head, face, and voice tremor (items 1-3), UL tremor of right and left UL (item 4) in three tasks (forward outstretched postural tremor, lateral "wing-beating" postural tremor, kinetic tremor), Archimedes spirals with both hands, handwriting with motor-dominant hand, and dot approximation task with both hands (items 6-8), and lower limb tremor and standing tremor (items 5 and 9). Each item was rated from 0 (no tremor) to 4 (severe tremor) with overall performance score of 0 to 64, calculated as the sum of subscale items. Higher scores indicated greater tremor severity.

Baseline of Cycle 2 up to Week 6 (Cycle length =12 weeks)
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score
時間枠:Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)

TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items on UL tremor (items 2-9). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score
時間枠:Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)

TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Percentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs)
時間枠:Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study(Week 36)

An adverse event (AE) is any untoward medical occurrence in subject administered pharmaceutical product. TEAEs of unilateral treatment period (Cycle 1) = AEs from first injection up to injection in the bilateral treatment period (Week 24). TEAEs of bilateral treatment period (Cycle 2) = AEs from injection in bilateral treatment period up to end of study (Week 36).

Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study(Week 36)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Merz Medical Expert、Merz Pharmaceuticals GmbH

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年2月24日

一次修了 (実際)

2023年4月26日

研究の完了 (実際)

2023年11月21日

試験登録日

最初に提出

2021年2月19日

QC基準を満たした最初の提出物

2021年2月19日

最初の投稿 (実際)

2021年2月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年10月29日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • M602011069
  • 2021-001988-24 (EudraCT番号)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。